<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2921">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04338906</url>
  </required_header>
  <id_info>
    <org_study_id>CLOCC-2020</org_study_id>
    <nct_id>NCT04338906</nct_id>
  </id_info>
  <brief_title>Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19</brief_title>
  <acronym>CLOCC</acronym>
  <official_title>Evaluation of the Efficacy and Safety of Camostat Mesilate + Hydroxychloroquine Combination Therapy in Hospitalized Patients With Moderate COVID-19 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Frankfurt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Georg Hospital Leipzig, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Schwabing Munich, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Missioklinik, Wuerzburg, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the efficacy and safety of hydroxychloroquine - camostat combination therapy in&#xD;
      hospitalized patients with moderate COVID-19 infection, CLOCC-Trial Primary Objectives: The&#xD;
      primary objective of this study is to demonstrate, that a combination therapy of&#xD;
      hydroxychloroquine and camostat (Foipan®) is superior to hydroxychloroquine + placebo in&#xD;
      participants with moderate COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ongoing pandemic with the novel coronavirus (SARS-CoV-2) poses a massive threat to public&#xD;
      health. SARS-CoV-2 is highly contagious and may lead to severe acute respiratory distress&#xD;
      syndrome in affected individuals. No therapeutic intervention has yet been approved for&#xD;
      COVID-19, and initial interventional studies with single agents showed only minimal&#xD;
      improvement in outcome or were not convincing in design. Therefore, the CLOCC trial will&#xD;
      evaluate the efficacy and safety of a combination therapy consisting of hydroxychloroquine,&#xD;
      which was used already as single agent with some effect, together with camostat mesylate in&#xD;
      hospitalized patients with moderate COVID-19 infection. The rationale for this combination&#xD;
      therapy stems from the observation that hydroxychloroquine interferes with viral entry and&#xD;
      replication through several mechanisms including changes in endosomal pH and in glycosylation&#xD;
      of the ACE2 receptor, which serves as entry receptor for SARS-CoV-2. Camostat acts as&#xD;
      inhibitor of the host cell serine protease TMPRSS2, which is needed to prime the viral S&#xD;
      protein for cell entry. Participants will be recruited in a total of 6 German centers, and&#xD;
      the trial will be randomized (1:1) and enrolled in either the hydroxychloroquine + placebo or&#xD;
      the hydroxychloroquine + camostat arm (7-day treatment). The trial will be carried out in a&#xD;
      double-blinded fashion. The primary efficacy outcome is the number of patients discharged by&#xD;
      day 14 (status 1 and 2 of a 7-point ordinal clinical status scale). Several secondary&#xD;
      outcomes regarding efficacy but also safety will be evaluated. Exploratory endpoints include&#xD;
      analysis of viral titers and the emergence of viral resistance in response to therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    lack of public funding; planned control arm with Hydroxychloroquine treatment showed out as not&#xD;
    being standard of care anymore as time evolved.&#xD;
  </why_stopped>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Evaluation of the efficacy and safety of hydroxychloroquine + camostat combination therapy in comparison to hydroxychloroquine + placebo in hospitalized patients with moderate COVID-19 infection, CLOCC-Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Not hospitalized</measure>
    <time_frame>day 14 from baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to improvement of 2 categories from admission on a 7-point ordinal scale</measure>
    <time_frame>day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants in each group with normalization of fever</measure>
    <time_frame>day 7 and day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants in each group with oxygen saturation &gt; 94% on room air for &gt;24h</measure>
    <time_frame>day 7 and day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to fever normalization (if febrile at baseline)</measure>
    <time_frame>within 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first negative SARS-CoV-2 PCR in NP swap (if pos. at baseline)</measure>
    <time_frame>within 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first negative SARS-CoV-2 PCR in lower respiratory tract specimens (sputum, bronchoalveolar lavage, tracheal aspirate) (if positive at baseline)</measure>
    <time_frame>within 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of oxygen therapy</measure>
    <time_frame>within 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants in each group with need for mechanical ventilation</measure>
    <time_frame>within 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>within 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Camostat + Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Camostat (400 mg tid) + hydroxychloroquine (400 mg bid day1, 200 mg bid d2-d7)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Hydroxychloroquine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive placebo (tid) + hydroxychloroquine (400 mg bid day1, 200 mg bid d2-d7)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camostat Mesilate</intervention_name>
    <description>400 mg tid, d1-d7</description>
    <arm_group_label>Camostat + Hydroxychloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Instead of Camostat Mesilate, tid, d1-d7</description>
    <arm_group_label>Placebo + Hydroxychloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>400 mg bid on day 1, 200 mg bid d2-d7</description>
    <arm_group_label>Camostat + Hydroxychloroquine</arm_group_label>
    <arm_group_label>Placebo + Hydroxychloroquine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants ≥18 years of age with SARS-CoV-2 infection confirmed by PCR before&#xD;
             randomization&#xD;
&#xD;
          -  Willing and able to provide written informed consent&#xD;
&#xD;
          -  Hospitalized and requiring medical care for COVID-19, (status 3 or 4 of 7-point&#xD;
             ordinal clinical status scale)&#xD;
&#xD;
          -  SpO2 ≥93% on room air&#xD;
&#xD;
          -  Evidence of pulmonary infiltrate on chest X ray/and or CT scan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years old&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Inability to take oral medication&#xD;
&#xD;
          -  Inability to provide informed written consent&#xD;
&#xD;
          -  Known hypersensitivity towards 4-aminoquinolines, e.g. hydroxychloroquine and/or&#xD;
             camostat&#xD;
&#xD;
          -  Use of hydroxychloroquine, chloroquine and or camostat within 6 months prior to&#xD;
             baseline&#xD;
&#xD;
          -  Patients with known retinopathy or macular degeneration Patients with known&#xD;
             glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
&#xD;
          -  Prolonged QTc-interval in baseline ECG (&gt;500 ms)&#xD;
&#xD;
          -  Concomitant medication associated with QTc-interval prolongation, which cannot be&#xD;
             withdrawn prior to study drug administration&#xD;
&#xD;
          -  Major comorbidities, possibly leading to increased unwanted side effects of study&#xD;
             drugs:&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2020</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Camostat</keyword>
  <keyword>Hydroxychloroquine</keyword>
  <keyword>Moderate COVID-10</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Camostat</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>3 Months after publication</ipd_time_frame>
    <ipd_access_criteria>Open</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

